- Home
- AES vs ROIV Comparison
AES vs ROIV Comparison
Compare AES & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- ROIV
- Stock Information
- Founded
- AES 1981
- ROIV 2014
- Country
- AES United States
- ROIV United Kingdom
- Employees
- AES N/A
- ROIV N/A
- Industry
- AES Electric Utilities: Central
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- AES Utilities
- ROIV Health Care
- Exchange
- AES Nasdaq
- ROIV Nasdaq
- Market Cap
- AES 7.1B
- ROIV 7.8B
- IPO Year
- AES 1991
- ROIV N/A
- Fundamental
- Price
- AES $10.09
- ROIV $10.99
- Analyst Decision
- AES Hold
- ROIV Buy
- Analyst Count
- AES 8
- ROIV 4
- Target Price
- AES $12.71
- ROIV $17.50
- AVG Volume (30 Days)
- AES 19.7M
- ROIV 5.1M
- Earning Date
- AES 05-01-2025
- ROIV 05-29-2025
- Dividend Yield
- AES 6.97%
- ROIV N/A
- EPS Growth
- AES 146.43
- ROIV N/A
- EPS
- AES 1.83
- ROIV N/A
- Revenue
- AES $12,119,000,000.00
- ROIV $29,053,000.00
- Revenue This Year
- AES $4.10
- ROIV N/A
- Revenue Next Year
- AES $2.95
- ROIV N/A
- P/E Ratio
- AES $5.50
- ROIV N/A
- Revenue Growth
- AES N/A
- ROIV N/A
- 52 Week Low
- AES $9.46
- ROIV $8.73
- 52 Week High
- AES $22.21
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- AES 42.85
- ROIV 52.59
- Support Level
- AES $9.58
- ROIV $10.59
- Resistance Level
- AES $10.11
- ROIV $11.37
- Average True Range (ATR)
- AES 0.48
- ROIV 0.32
- MACD
- AES -0.16
- ROIV -0.01
- Stochastic Oscillator
- AES 19.47
- ROIV 52.23
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.